Multiple Myeloma Market Insight
DelveInsight’s ‘Multiple Myeloma (MM)-Market Insights, Epidemiology and Market Forecast—2030’ report delivers an in-depth understanding of the MM, historical and forecasted epidemiology as well as the MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), Japan and China.
The MM market report provides current treatment practices, emerging drugs, MM market share of the individual therapies, current and forecasted MM market size from 2017 to 2030 segmented by eight major markets. The Report also covers current MM treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.
- The United States
- EU5 (Germany, France, Italy, Spain and the United Kingdom)
Study Period: 2017–2030
Multiple Myeloma (MM): Disease Understanding and Treatment Algorithm
Multiple Myeloma Overview
According to the American Cancer Society, Multiple myeloma is a cancer of plasma cells. In general, when plasma cells become cancerous and grow out of control, this is called multiple myeloma. The plasma cells make an abnormal protein (antibody) known by several different names, including monoclonal immunoglobulin, monoclonal protein (M-protein), M-spike, or paraprotein. Normal plasma cells are found in the bone marrow and are a significant part of the immune system. Multiple myeloma is the second most common blood cancer diagnosis, after non-Hodgkin lymphoma, in the United States. MM is slightly more prevalent in males compared to females. Myeloma incidence is strongly related to age, with the highest incidence rates being in older people and most frequently diagnosed among people aged 65–74. Approximately 95% of cases are diagnosed at a distant stage or metastatic stage and 5-year relative survival rate for this stage is around 53%. Most of the researchers are unaware of the exact cause of multiple myeloma. However, they have made progress in understanding how certain changes in DNA can make plasma cells become cancerous. DNA is the chemical that transfers the instructions for nearly everything the cells do in the body. Patients with active myeloma generally receive treatment aimed at reducing or at least providing relief from symptoms and reducing the number of myeloma cells in the bone marrow.
Multiple Myeloma Diagnosis
Multiple myeloma is often diagnosed based on tests, the patient’s symptoms and the doctor’s physical exam of the patient. A diagnosis of multiple myeloma requires either:
1. A plasma cell tumor (proven by biopsy) or at least 10% plasma cells in the bone marrow
2. At least one of the following:
- High blood calcium level
- Poor kidney function
- Low red blood cell counts (anemia)
- Holes in the bones from a tumor found on imaging studies (CT, MRI, PET scan)
- Increase in one type of light chain in the blood so that one type is 100 times more common than the other
- 60% or more plasma cells in the bone marrow
Multiple Myeloma Treatment
The main treatment options include stem cell transplant, chemotherapy, targeted therapy, corticosteroids, proteasome inhibitors, immunomodulators, monoclonal antibodies, surgery, and radiation therapy. Also, the survival of patients with myeloma has improved due to the development and approval of new treatments. MM treatment strategies have also evolved with the emergence of new therapies with a novel mechanism of action and also with more complex combination regimens being used, such as quadruplets, triplets, and doublets.
Multiple Myeloma (MM) Epidemiology
The Multiple Myeloma epidemiology division provide the insights about historical and current Multiple Myeloma patient pool and forecasted trend for each eight major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The MM epidemiology division provides insights about historical and current patient pool and forecasted trends for each eight major countries. The Multiple Myeloma epidemiology data are studied through Multiple Myeloma possible division to give a better understanding of the Disease scenario in the 8MM.
The disease epidemiology covered in the report provides historical as well as forecasted Multiple Myeloma epidemiology [segmented as Total Incidence of Multiple Myeloma, Total Symptomatic Cases of Multiple Myeloma, Total Incident Cases of Multiple Myeloma Segmented by Gender, Total Diagnosed cases of Multiple Myeloma by Age Distribution, Total Cases of Multiple Myeloma by Line of Treatment] scenario of Multiple Myeloma in the 8MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China from 2017 to 2030
Country Wise- Multiple Myeloma Epidemiology
- In the year 2020, the total incident case of Multiple Myeloma was 91,693 cases in the 8MM. The United States, in 2020, accounted for 32,270 cases (the highest number), which will probably rise by the year 2030. Among the EU-5 countries, the highest number of incident cases of Multiple Myeloma in the year 2020, was in Germany. In China, the total number of incident cases of Multiple Myeloma was 21,116 in 2020, and this number is expected to rise throughout the forecast period.
- The overall number of symptomatic cases of Multiple Myeloma in the 8MM was 80,715, and these cases are expected to rise by 2030.
- Males are more likely to develop Multiple Myeloma than females (about 55 percent of cases). When it comes to age-specific Multiple Myeloma cases, the age group 65–74 years has by far the most, followed by 75–84 years and 55–64 years.
- In the 8MM, the total cases of Multiple Myeloma by treatment line were 23,581 cases for frontline transplant-eligible patients, 49,699 cases for frontline transplant-ineligible patients, 44,955 cases for second-line patients, 23,498 cases for third-line patients, and 10,236 cases for fourth-line plus patients, in the year 2020.
Multiple Myeloma Drug Chapters
Drug chapter segment of the Multiple Myeloma report encloses the detailed analysis of Multiple Myeloma marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Multiple Myeloma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Multiple Myeloma Marketed Drugs
Blenrep (Belantamab Mafodotin /GSK2857916): GlaxoSmithKline
GlaxoSmithKline’s lead candidate, Belantamab Mafodotin (GSK2857916) is a first-in-class, anti-BCMA immunoconjugate with an afucosylated, humanized IgG1 anti-BCMA monoclonal antibody conjugated by a protease-resistant maleimidocaproyl linker to a microtubule-disrupting agent, monomethyl auristatin F (MMAF). The drug linker technology is licensed from Seattle Genetics; monoclonal antibody is produced using POTELLIGENT Technology licensed from BioWa. It was approved by UDFDA and the European Commission in August 2020. This drug has received orphan drug designation from the EMA and the US FDA for multiple myeloma. Apart from this, the EMA and the US FDA have also granted PRIME designation and Breakthrough Therapy designation, respectively.
Abecma (Idecabtagene vicleucel/bb2121/ ide-cel): Bristol-Myers Squibb/Bluebird bio
Abecma (ide-cel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous chimeric antigen receptor (CAR) T cell immunotherapy co-developed, and co-promoted by Bristol Myers Squibb and Bluebird bio for the treatment of adult patients with multiple myeloma who have received at least three prior therapies. In March 2021, the USFDA approved Abecma for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. This is the first FDA-approved cell-based gene therapy for multiple myeloma.
Pepaxto (melflufen/ melphalan flufenamide): Oncopeptides AB
Pepaxto is a first-in-class anti-cancer peptide-drug conjugate that rapidly produces an alkylating payload into tumor cells. It is promptly taken up by myeloma cells due to its high lipophilicity and is immediately cleaved by peptidases to deliver an entrapped hydrophilic alkylator payload. Peptidases play a key role in protein homeostasis and feature in cellular processes such as cell-cycle progression and programmed cell death. In February 2021, the USFDA approved Pepaxto in combination with dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody.
Sarclisa (Isatuximab): Sanofi
Sarclisa— a product of Sanofi is a monoclonal antibody that binds to the CD38 receptor on multiple myeloma cells. It is manufactured and designed to initiate programmed tumor cell death (apoptosis) and immunomodulatory activity. In December 2017, Isatuximab received Orphan Designation for the treatment of patients with Relapsed or Refractory Multiple Myeloma by the US FDA and EMA.
Xpovio (Selinexor): Karyopharm
Karyopharm’ potential candidate Selinexor is an oral, first-in-class, selective inhibitor of nuclear export also known as SINE, compound. It has been approved by the US FDA in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. In April 2021, EMA validated the Company's Type II Variation MAA, which seeks to expand the currently authorized indication for Nexpovio in the European Union to include, in combination with Velcade (bortezomib) and low-dose dexamethasone, the treatment of adult patients with multiple myeloma who have received at least one prior therapy. Validation of the application confirms the submission is complete to begin the EMA's review process.
Darzalex (Daratumumab): Janssen Biotech
Darzalex (daratumumab) is a prescription medicine used to treat a type of blood cancer called multiple myeloma. Darzalex is not chemotherapy. It is a human IgG1k monoclonal antibody that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells. In November 2015, Darzalex first received the US FDA approval as a monotherapy for patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent, or who are double refractory to a PI and an immunomodulatory agent. Recently, in April 2020, the US FDA approved Darzalex Faspro (daratumumab and hyaluronidase-fihj), a new subcutaneous formulation of daratumumab. Darzalex Faspro is approved in four regimens across five indications in multiple myeloma patients, including newly diagnosed, transplant-ineligible patients as well as relapsed or refractory patients.
Products detail in the report…
Multiple Myeloma Emerging Drugs
Venetoclax (ABT-199): AbbVie and Roche
Venetoclax (Venclexta, Venclyxto) is an oral B-cell lymphoma-2 (BCL-2) inhibitor developed by AbbVie and Genentech. It is used for the treatment of adult patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) and in combination with azacitidine or decitabine or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy. In nonclinical studies, venetoclax has demonstrated cytotoxic activity in tumor cells that overexpress BCL-2. In March 2019, the US FDA placed a partial clinical hold on Venetoclax’s multiple myeloma trials after new safety concerns were raised during a review of the BELLINI Phase III trial (NCT02755597). In June 2019, the US FDA removed the partial clinical hold based upon agreement on revisions to the CANOVA study protocol (Myeloma Positive for the t(11;14) Genetic Abnormality), including new risk mitigation measures, protocol-specified guidelines, and updated futility criteria (AbbVie News Center, 2019).
Ciltacabtagene Autoleucel (cilta-cel/ JNJ-4528/ JNJ-68284528/ LCAR-B38M): Janssen Biotech/Nanjing Legend Biotech
Ciltacabtagene Autoleucel is currently being investigated for the treatment of patients with multiple myeloma who have received at least three prior regimens, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody, and have documented disease progression within 12 months of starting the most recent therapy, or are double refractory to an immunomodulatory drug and a proteasome inhibitor. This product is being evaluated under licensing and collaboration agreements between Janssen and Legend Biotech. In the first quarter of 2021, the rolling submission of a Biologics License Application (BLA) to the USFDA was completed by Janssen, for cilta-cel, for the treatment of adults with relapsed or refractory multiple myeloma. Additionally, in April 2021, the company has also submitted the MAA to the EMA for cilta-cel (Legend Biotech, 2021b).
REGN5458: Regeneron Pharmaceuticals
REGN5458 is a BCMAxCD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma. BCMA (B-cell maturation antigen) is a protein that is typically over-expressed on multiple myeloma cells. In December 2019, the company presented the results at the American Society of Hematology (ASH) Annual Meeting. Currently, REGN5458 monotherapy is being investigated in an open-label, Phase I/II (NCT03761108) dose-escalation trial in patients with relapsed or refractory multiple myeloma who are at least triple refractory to existing therapeutic options, including proteasome inhibitors, immunomodulatory drugs, and CD38 antibody treatments.
Iberdomide (CC-220): Bristol-Myers Squibb/Celgene
Iberdomide is an investigational cereblon E3 ligase modulator compound with enhanced tumoricidal and Immunostimulatory activities that induces degradation of transcription factors Aiolos and Ikaros, thereby inhibiting the growth of myeloma cells in vitro. In pre-clinical models, iberdomide has demonstrated the ability to destroy tumor cells, stimulate an immune response, overcome resistance to immunomodulatory drugs, and synergize with dexamethasone, daratumumab, and bortezomib (Celgene Corporation, 2019). In December 2018, the US FDA has granted orphan drug designation to iberdomide for the treatment of multiple myeloma.
Products detail in the report…
Multiple Myeloma Market Outlook
According to DelveInsight, the Multiple Myeloma market size in the 8MM is expected to change at a CAGR of 4.3% during the study period (2017–2030). In the total market size of Multiple Myeloma in the 8MM, the United States accounted for the highest market size in 2020 followed by Japan, Germany, and France.
The United States Market Outlook
In the United States, the total market size of Multiple Myeloma is expected to increase at a CAGR of 4.0% during the study period (2017–2030).
EU-5 Countries: Market Outlook
In EU-5 countries, the total market size of Multiple Myeloma is expected to increase at a CAGR of 4.8% during the study period (2017–2030).
Japan Market Outlook
In Japan, the total market size of Multiple Myeloma is expected to increase at a CAGR of 3.9% during the study period (2017–2030).
China Market Outlook
In China, the total market size of Multiple Myeloma is expected to increase at a CAGR of 6.2% during the study period (2017–2030).
Multiple Myeloma Pipeline Development Activities
The drugs which are in pipeline include:
- Venetoclax (ABT-199): AbbVie and Roche
- JNJ-68284528 (LCAR-B38M/JNJ-4528): Janssen Biotech/Nanjing Legend Biotech
- Keytruda (Pembrolizumab): Merck Sharp & Dohme Corp.
- Cetrelimab (JNJ-63723283): Janssen Research & Development
- REGN5458: Regeneron Pharmaceuticals
- Felzartamab (MOR202): MorphoSys AG/I-Mab Biopharma
- Chidamide (Epidaza): Chipscreen Biosciences
- Iberdomide (CC-220): Bristol-Myers Squibb/Celgene
- Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy: RAPA Therapeutics
- Encorafenib in combination with Binimetinib: Pfizer (Array Biopharma)
- CLR 131 (131-CLR1404): Cellectar Biosciences
- BL-8040: BioLineRx
- GVAX (GM-CSF) Vaccine: Celgene/Aduro Biotech
- ECT-001: ExCellThera
- TAK-079: Takeda
- GBR 1342 (ISB 1342): Glenmark (Ichnos Sciences SA)
- P-BCMA-101 CAR-T cells: Poseida Therapeutics
- Opdivo (Nivolumab): Bristol-Myers Squibb
- PBCAR269A: Precision BioSciences
- MP0250: Molecular Partners AG
- Teclistamab (JNJ-7957; JNJ-64007957): Janssen Pharmaceutical
- Descartes-11: Cartesian Therapeutics
- Imfinzi (Durvalumab): AstraZeneca
- Imbruvica (Ibrutinib): Abbvie (Pharmacyclics) and Johnson & Johnson
Products detail will be provided in the report…
Pipeline Development Activities
- In June 2021, the Janssen Pharmaceutical Companies of Johnson & Johnson announced that the USFDA has granted Breakthrough Therapy Designation for teclistamab in the treatment of relapsed or refractory multiple myeloma. This distinction for teclistamab, an off-the-shelf, T-cell redirecting, a bispecific antibody targeting both BCMA and CD3 receptors, follows a PRIME designation from the EMA received earlier this year.
- In May 2021, Oncopeptides has announced positive results from the OCEAN study, which compared the effectiveness and safety of melflufen with pomalidomide in patients with relapsed refractory multiple myeloma. The phase III OCEAN study is a global, randomized, head-to-head, open-label study, evaluating the efficacy and safety of melflufen and dexamethasone, versus pomalidomide and dexamethasone in patients with relapsed refractory multiple myeloma who have received 2-4 prior therapies.
- In May 2021, the USFDA granted priority review to the Biologics License Applications (BLA) for ciltacabtagene autoleucel for the treatment of patients with relapsed/refractory multiple myeloma. The regulatory agency is expected to decide on the application by November 29, 2021, under the Prescription Drug User Fee Act.
- In April 2021, Legend Biotech announced the submission of a MAA to the EMA seeking approval of ciltacabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma. The EMA’s Committee for Medicinal Products for Human Use (CHMP) granted accelerated assessment for this MAA.
Multiple Myeloma Drugs Uptake
Among the IMid’s agent lenalidomide (Revlimid) dominates the Multiple Myeloma market in the 8MM, where it is included in all lines of Multiple Myeloma therapy either as monotherapy or in combination with other drugs. According to a settlement deal between Celgene and Natco Pharma, a limited generic entry will begin in March 2022 for this candidate, and from January 31, 2026, generic entry will be permitted without volume limitation in the United States. Despite the loss of patent exclusivity in important markets and the approval of other prospective pipeline candidates, lenalidomide is expected to have a significant presence in 2030. Among emerging therapies, Ciltacabtagene autoleucel (JNJ-68284528) from Janssen Biotech/Nanjing Legend Biotech is expected to give tough competition to Idecabtagene Vicleucel.
Access and Reimbursement Scenario in Multiple Myeloma Therapies
- In March 2019, the Janssen Pharmaceutical Companies of Johnson & Johnson has announced that the National Institute for Health and Care Excellence (NICE) has recommended Darzalex (daratumumab) plus Velcade (bortezomib) and dexamethasone (DVd) for use within the Cancer Drugs Fund (CDF), as an option for treating relapsed multiple myeloma in people who have had one previous treatment. Patients at the second line will now have access to a treatment combination, which NICE accepts had a ‘clinically important and statistically significant effect on progression-free survival.
- With effect from August 2020, the Medicaid and NC Health Choice programs cover belantamab mafodotin-blmf for injection, for intravenous use (Blenrep) for use in the Physician Administered Drug Program (PADP) when billed with HCPCS code. Belantamab mafodotin-blmf is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent (NCDHHS, 2020).
To keep up with current market trends, we take KOLs and SME’s opinion working in Multiple Myeloma domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Multiple Myeloma market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Multiple Myeloma Market by using various Competitive Intelligence tools that includes – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
- The report covers the descriptive overview of Multiple Myeloma, explaining its causes, signs and symptoms, pathophysiology and currently available therapies.
- Comprehensive insight has been provided into the Multiple Myeloma epidemiology and treatment in the 8MM.
- Additionally, an all-inclusive account of both the current and emerging therapies for Multiple Myeloma are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
- A detailed review of Multiple Myeloma market; historical and forecasted is included in the report, covering drug outreach in the 8MM.
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Multiple Myeloma market.
- In the coming years, Multiple Myeloma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies and academics are working to assess challenges and seek opportunities that could influence Multiple Myeloma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- Major players are involved in developing therapies for Multiple Myeloma. Launch of emerging therapies, will significantly impact the Multiple Myeloma market.
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Multiple Myeloma.
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Multiple Myeloma Report Insights
- Patient Population
- Therapeutic Approaches
- Multiple Myeloma Pipeline Analysis
- Multiple Myeloma Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Multiple Myeloma Report Key Strengths
- 10 Years Forecast
- 8MM Coverage
- Multiple Myeloma Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Multiple Myeloma Report Assessment
- SWOT Analysis
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Conjoint Analysis
- Market Attractiveness
- Market Drivers and Barriers
- What was the Multiple Myeloma Market share (%) distribution in 2017 and how it would look like in 2030?
- What would be the Multiple Myeloma total market Size as well as market size by therapies across the 8MM during the study period (2017–2030)?
- What are the key findings pertaining to the market across the 8MM and which country will have the largest Multiple Myeloma market size during the study period (2017–2030)?
- At what CAGR, the Multiple Myeloma market is expected to grow in the 8MM during the study period (2017–2030)?
- What would be the Multiple Myeloma market outlook across the 8MM during the study period (2017–2030)?
- What would be the Multiple Myeloma market growth till 2030 and what will be the resultant market size in the year 2030?
- How would the market drivers, barriers and future opportunities affect the market dynamics and a subsequent analysis of the associated trends?
- Multiple Myeloma patient types/ pool where unmet need is more and whether emerging therapies will be able to address the residual unmet need?
- How emerging therapies are performing on the parameters like efficacy, safety, route of administration (RoA), treatment duration and frequencies based on their clinical trial results?
- Among the emerging therapies, what are the potential therapies which are expected to disrupt the Multiple Myeloma market?
- What is the disease risk, burden and unmet needs of the Multiple Myeloma?
- What is the historical Multiple Myeloma patient pool in eight major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) Japan and China?
- What would be the forecasted patient pool of Multiple Myeloma in 7 major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) Japan and China?
- What will be the growth opportunities in the 8MM with respect to the patient population pertaining to Multiple Myeloma?
- Out of all the 8MM countries, which country would have the highest Incident population of Multiple Myeloma during the study period (2017–2030)?
- At what CAGR the population is expected to grow in the 8MM during the study period (2017–2030)?
- What are the various recent and upcoming events which are expected to improve the diagnosis of Multiple Myeloma?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
- What are the current options for the treatment of Multiple Myeloma along with the approved therapy?
- What are the current treatment guidelines for the treatment of Multiple Myeloma in the US, Europe Japan and China?
- What are the Multiple Myeloma marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
- How many companies are developing therapies for the treatment of Multiple Myeloma?
- How many therapies are developed by each company for the treatment of Multiple Myeloma?
- How many emerging therapies are in mid stage, and late stage of development for the treatment of Multiple Myeloma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Multiple Myeloma therapies?
- What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Multiple Myeloma and their status?
- What are the key designations that have been granted for the emerging therapies for Multiple Myeloma?
- What are the global historical and forecasted market of Multiple Myeloma?
Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving the Multiple Myeloma market.
- To understand the future market competition in the Multiple Myeloma market and Insightful review of the key market drivers and barriers.
- Organize sales and marketing efforts by identifying the best opportunities for Multiple Myeloma in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom) Japan and China.
- Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.
- Organize sales and marketing efforts by identifying the best opportunities for Multiple Myeloma market.
- To understand the future market competition in the Multiple Myeloma market.